These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24574066)

  • 1. Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit.
    Cowan A; Raffa RB; Tallarida CS; Tallarida RJ; Christoph T; Schröder W; Tzschentke TM
    Eur J Pain; 2014 Sep; 18(8):1148-56. PubMed ID: 24574066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia.
    Schröder W; Tzschentke TM; Terlinden R; De Vry J; Jahnel U; Christoph T; Tallarida RJ
    J Pharmacol Exp Ther; 2011 Apr; 337(1):312-20. PubMed ID: 21262850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
    Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T
    Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain.
    Schiene K; De Vry J; Tzschentke TM
    J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
    Tzschentke TM; Christoph T; Kögel B; Schiene K; Hennies HH; Englberger W; Haurand M; Jahnel U; Cremers TI; Friderichs E; De Vry J
    J Pharmacol Exp Ther; 2007 Oct; 323(1):265-76. PubMed ID: 17656655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice.
    Christoph T; Schröder W; Tallarida RJ; De Vry J; Tzschentke TM
    J Pharmacol Exp Ther; 2013 Dec; 347(3):794-801. PubMed ID: 24051022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of tapentadol on neurons in the locus coeruleus.
    Torres-Sanchez S; Alba-Delgado C; Llorca-Torralba M; Mico JA; Berrocoso E
    Neuropharmacology; 2013 Sep; 72():250-8. PubMed ID: 23664814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of μ-opioid and noradrenaline reuptake inhibition in the modulation of pain responsive neurones in the central amygdala by tapentadol in rats with neuropathy.
    Gonçalves L; Friend LV; Dickenson AH
    Eur J Pharmacol; 2015 Feb; 749():151-60. PubMed ID: 25576174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tramadol antinociception is potentiated by clonidine through α₂-adrenergic and I₂-imidazoline but not by endothelin ET(A) receptors in mice.
    Andurkar SV; Gendler L; Gulati A
    Eur J Pharmacol; 2012 May; 683(1-3):109-15. PubMed ID: 22449379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mu-opioid and noradrenergic α(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats.
    Bee LA; Bannister K; Rahman W; Dickenson AH
    Pain; 2011 Jan; 152(1):131-139. PubMed ID: 21187272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo characterization of tapentadol metabolites.
    Terlinden R; Kogel BY; Englberger W; Tzschentke TM
    Methods Find Exp Clin Pharmacol; 2010; 32(1):31-8. PubMed ID: 20383344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tapentadol hydrochloride: a centrally acting oral analgesic.
    Wade WE; Spruill WJ
    Clin Ther; 2009 Dec; 31(12):2804-18. PubMed ID: 20110020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice.
    Kögel B; De Vry J; Tzschentke TM; Christoph T
    Neurosci Lett; 2011 Mar; 491(2):104-7. PubMed ID: 21232580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview].
    Tzschentke TM; Christoph T; Schröder W; Englberger W; De Vry J; Jahnel U; Kögel BY
    Schmerz; 2011 Feb; 25(1):19-25. PubMed ID: 21258822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
    Kögel B; Christoph T; Strassburger W; Friderichs E
    Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol.
    Tzschentke TM; Christoph T; Kögel BY
    CNS Drugs; 2014 Apr; 28(4):319-29. PubMed ID: 24578192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The noradrenergic component in tapentadol action counteracts μ-opioid receptor-mediated adverse effects on adult neurogenesis.
    Meneghini V; Cuccurazzu B; Bortolotto V; Ramazzotti V; Ubezio F; Tzschentke TM; Canonico PL; Grilli M
    Mol Pharmacol; 2014 May; 85(5):658-70. PubMed ID: 24516101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of dezocine, pentazocine and tapentadol on antinociception and physical dependence.
    Ahsan MZ; Zhao MJ; Shoaib RM; Zhang Y; Wang YX
    Life Sci; 2021 Nov; 285():119996. PubMed ID: 34597607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, placebo-controlled trial comparing the effects of tapentadol and oxycodone on gastrointestinal and colonic transit in healthy humans.
    Jeong ID; Camilleri M; Shin A; Iturrino J; Boldingh A; Busciglio I; Burton D; Ryks M; Rhoten D; Zinsmeister AR
    Aliment Pharmacol Ther; 2012 May; 35(9):1088-96. PubMed ID: 22348605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.
    Tham SM; Angus JA; Tudor EM; Wright CE
    Br J Pharmacol; 2005 Mar; 144(6):875-84. PubMed ID: 15778704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.